To market and distribute four products of USpharma Windlas in USA
Granules India announced that its wholly owned subsidiary, Granules Pharmaceuticals Inc. has acquired the exclusive rights from USpharma Windlas, LLC to market and distribute four products in the USA.USpharma Windlas through its subsidiaries (First Time US Generics and Liberty) holds ANDAs for Fingolimod, Prasugrel, Dronedarone and Lurasidone. USpharma Windlas will receive milestone payments and share of the profits from commercial sales.
Granules Pharmaceuticals Inc. will be responsible for the marketing and distribution of the products in the United States, subject to approval of the USFDA.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app